Efficacy and Safety of PRM-151 in Myelofibrosis
Verstovsek S et al. PRM-151 in myelofibrosis: Durable efficacy and safety at 72 weeks. Proc ASH 2015;Abstract 56.
Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
|